Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Alexandre Just

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Nature Communications|December 1, 2020
Lkb1 suppresses amino acid-driven gluconeogenesis in the liverPierre-Alexandre Just, Sara Charawi, Raphaël G P Denis, et al.
Nature Communications|March 18, 2021
Author Correction: Lkb1 suppresses amino acid-driven gluconeogenesis in the liverPierre-Alexandre Just, Sara Charawi, Raphaël G P Denis, et al.
JCO Oncology Practice|November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian CancerClaudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerRomain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
Gynecologic Oncology|January 16, 2022
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancerGuillaume Beinse, Marie-Aude Le Frere Belda, Pierre-Alexandre Just, et al.
JCO Precision Oncology|January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialFélix Blanc-Durand, Benoit You, Yahia Adnani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trialGuillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Archives of Pathology & Laboratory Medicine|December 8, 2024
Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?Amel Kime, Guillaume Bataillon, Isabelle Treilleux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2025
Unravelling the tumor microenvironment and PD-L1 expression across tissue type in high-grade serous ovarian cancer in the NeoPembrOV/GINECO phase II randomized trialLaetitia Collet, Maude Ardin, David Venet, et al.
Nature Communications|December 1, 2020
Lkb1 suppresses amino acid-driven gluconeogenesis in the liverPierre-Alexandre Just, Sara Charawi, Raphaël G P Denis, et al.
Nature Communications|March 18, 2021
Author Correction: Lkb1 suppresses amino acid-driven gluconeogenesis in the liverPierre-Alexandre Just, Sara Charawi, Raphaël G P Denis, et al.
JCO Oncology Practice|November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian CancerClaudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancerRomain Boidot, Michael G B Blum, Marie-Pierre Wissler, et al.
Gynecologic Oncology|January 16, 2022
Development and validation of a RNAseq signature for prognostic stratification in endometrial cancerGuillaume Beinse, Marie-Aude Le Frere Belda, Pierre-Alexandre Just, et al.
JCO Precision Oncology|January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialFélix Blanc-Durand, Benoit You, Yahia Adnani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trialGuillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Pageof 8